Literature DB >> 18536037

Deep brain stimulation in Parkinson's disease following fetal nigral transplantation.

Jan Herzog1, Oliver Pogarell, Marcus O Pinsker, Andreas Kupsch, Wolfgang H Oertel, Olle Lindvall, Günther Deuschl, Jens Volkmann.   

Abstract

OFF-period dyskinesias have been reported as a consequence of fetal nigral transplantation for Parkinson's disease. This type of dyskinesias may appear in patients even in the prolonged absence of antiparkinson medication and be aggravated by levodopa. Therefore, pharmacological therapeutic approaches in these patients are limited. Here we report two patients with bilateral fetal nigral grafts in the caudate and putamen subjected to deep brain stimulation (DBS) of the globus pallidus internus (GPi) or subthalamic nucleus (STN). Clinical assessment was performed according to UPDRS and the clinical dyskinesia rating scale. In both patients, we found significant improvement in OFF-period symptoms as well as levodopa-induced dyskinesias. However, only GPi-DBS led to a significant reduction of OFF-period dyskinesias whereas STN-DBS did not influence dyskinesias unrelated to external dopaminergic application. These findings, based on two case reports, highlight the pivotal role of the GPi in mediating dyskinesia-related neural activity within the basal ganglia loop. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18536037     DOI: 10.1002/mds.21768

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Cell therapeutics in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 2.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

3.  Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety.

Authors:  Nader Pouratian; Sandeep Thakkar; Won Kim; Jeff M Bronstein
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-09-04

Review 4.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

Review 5.  Treatment of Parkinson's disease using cell transplantation.

Authors:  Olle Lindvall
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

Review 6.  Cell-based therapies for Parkinson disease—past insights and future potential.

Authors:  Roger A Barker; Janelle Drouin-Ouellet; Malin Parmar
Journal:  Nat Rev Neurol       Date:  2015-08-04       Impact factor: 42.937

7.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.

Authors:  Zinovia Kefalopoulou; Marios Politis; Paola Piccini; Niccolo Mencacci; Kailash Bhatia; Marjan Jahanshahi; Håkan Widner; Stig Rehncrona; Patrik Brundin; Anders Björklund; Olle Lindvall; Patricia Limousin; Niall Quinn; Thomas Foltynie
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

Review 8.  Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia.

Authors:  Elisabetta Tronci; Camino Fidalgo; Manolo Carta
Journal:  Parkinsons Dis       Date:  2015-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.